CTRI/2021/03/032373尚未招募4 期
A prospective, open label, 3 arm, parallel group comparative study toevaluate the effect of short term treatment with vitamin Dâ?? and vitamin Con glycemic control and oxidative stress markers in inadequatelycontrolled type-2 diabetes mellitus.
Shingare Sujata Prakash0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female patients between 30-75yrs of age, diagnosed with
- •type-2 diabetes mellitus within last 1 year of collection of data.
- •2. Receiving oral anti-diabetic medications but does not need insulin
- •within last 1 year i.e. from the date of diagnosis of type-2 diabetes
- •3. Patients with HbA1c value more >7% and <9% despite therapy.
排除标准
- •1. DM other than T2DM.
- •2. Patients with abnormal liver function tests.
- •3. Patients with abnormal renal function tests.
- •4. Patients with cardiovascular or respiratory insufficiency.
- •5. Acutely ill patients.
- •6. Pregnant and nursing women.
研究者
相似试验
尚未招募
3 期
A clinical trial study of oral Roflumilast 0.5mg Tablet and combination therapy of Roflumilast 0.5 mg tablet plus Salmeterol 25mcg oral inhaler and combination therapy of Roflumilast 0.5 mg tablet plus Tiotropium 9mcg oral inhaler in adult patients with Chronic Obstructive Pulmonary Disease.CTRI/2014/01/004370MSN Laboratories Pvt Ltd300
尚未招募
3 期
Management of moderate malnutrition in children presented with acute illnessCTRI/2023/11/060203Center for Public Health Kinetics
尚未招募
4 期
A randomized clinical study to compare patient satisfaction and clinical outcome with three different nasal pack dressings available and that are used after nasal surgeryCTRI/2024/06/069152Dr Akhil Pratap Singh Trial Investigator
进行中（未招募）
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0Level: PTClassification code 10020161EUCTR2004-002254-59-GBGilead Sciences Limited220
进行中（未招募）
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0 Level: PT Classification code 10020161EUCTR2004-002254-59-IEGilead Sciences Limited220